Form D · Biotechnology

Proteocyte Diagnostics Inc.

Toronto, A6 · CIK 0001987946

Offering snapshot reported Dec 18, 2023 · SEC filing

Reported sold
$36.9K
Offering amount: $36.9K
Investors reported
1
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Dec 4, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 18, 2023Initial$36,925No comparison1SEC filing
Jul 31, 2023Initial$37,915No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-499990
Total Offering Amount represents the principal amount of the Note. Based on Bank of Canada exchange rate reported on December 4, 2023 CAD$1.00:USD$0.7385.
Convertible Note (the ?Note?) in the principal amount of C$50,000. The type and class of share that the Note converts into will be determined at a future date (upon a future "qualified financing"). The note carries an interest rate of 8% per annum.

Source: Form D, filed Dec 18, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steven Arless Director
Mark Hammer Executive
John Jordan Director, Executive
Anthony Morlandt Director
Barrie Renick Director
Carlo Sistilli Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Mars Centre, South Tower 101 College Street, Suite 200
Toronto, A6, M5G 1L7